The Global Antiviral Therapeutics Technologies Market is expected to reach $xx Mn in 2026 from $xx Mn in 2020, at a CAGR of xx% during forecast period.
Market Overview & Dynamics:
Antiviral therapy is one of the aspects of virology, since it has successfully employed basic science to generate very effective treatments for serious viral infections. Antiviral therapies have been developed against various viral diseases affecting humans like HIV, Hepatitis, Influenza and others. The sudden outbreak of the COVID-19 pandemic has made a strong impact on the global antiviral therapy market. With the development of this pandemic, the number of clinical studies on antiviral therapy, including remdesivir, chloroquine and hydroxychloroquine, lopinavir/ritonavir, ribavirin, arbidol, interferon, favipiravir and othrs has been increasing. However, the efficacy of these antiviral drugs for COVID-19 remains controversial. Remdesivir is the only Food and Drug Administration-approved drug for the treatment of COVID-19.
Rising prevalence of various viral diseases is expected to create new opportunities for development of new products and will drive the market growth.
As per the news released on 3rd February 2020, 1126 clinical trials are going on for antiviral therapeutics. These trials are mainly driven by the growing burden of viral infections worldwide. According to The Joint United Nations Programme on HIV/AIDS (UNAIDS), approximately 38.0 million people globally were living with HIV in 2019.
Moreover, strong research and development pipelines of the major players coupled with, increasing product launches, are of the key drivers in the antiviral therapeutics market growth. According to the recent data by Centers for Disease control and Prevention (CDC) in 2016, reported more than 38,000 new HIV infections in US.
Many viral infections remain in the latent stage for a prolonged period and their diagnosis and treatment poses challenges
Continuous efforts in the direction of research on antiviral therapies have improved the quality of life of patients suffering from viral infections. However, the appearance of newer viral infections worldwide and the emergence of multidrug-resistant strains and its transmission have put forward greater challenges to the clinical utility of antiviral therapies
The report covers the detailed analysis of global Antiviral Therapeutics Technologies industry with the classifications of the market based on type, application and technology. Analysis of past market dynamics from 2016 to 2019 is given in the report, which will help readers to benchmark the past trends with current market scenarios with the key players contribution in it.
The report has profiled sixteen key players in the market from different regions. However, report has considered all market leaders, followers and new entrants with investors while analyzing the market and estimation the size of the same. Increasing R&D activities in each region are different and focus is given on the regional impact on the availability of advanced technology and new product launches are analyzed and report has come up with recommendations for future hot spot in APAC region.
Global Antiviral Therapeutics Technologies Market Segment Analysis:
The global Antiviral Therapeutics Technologies market is segmented on the basis of product, application and technology. The product segment is divided into generic and branded drugs. The branded drugs segment held a dominant share in 2018 and is expected to continue the dominance throughout forecast period. The high availability of these branded drugs and high prescription and price rate is responsible for the segment growth.
Based on application, the HIV/AIDS segment is expected to be the largest revenue holder during the forecast period. This is attributed due to large number of HIV patient pool present worldwide. For instance, as per the data published by UNAIDS, in 2017, around 37 million of the global population is living with HIV. The prevalence of HIV among the adults was estimated to be 0.8%. Therefore, increase in consumption of HIV anti-viral drugs for combating infection is the major factor that drives the growth of anti-viral therapies market for HIV segment.
On the basis on technology segment, various technologies like gene therapy, antisense, RNAi and Nanotechnology are being applied for the treatment of viral infections. Amongst these technologies, the nanotechnology segment is anticipated to stimulate the market growth in upcoming years. With the advent of nanotechnology, it has been possible to comprehend the cellular mechanisms of the living cells and to develop relevant technologies which facilitate early diagnosis and treatment of various viral infections.
Some of its applications consist of drug and gene delivery; use of fluorescent biological labels, detection of proteins, pathogens, and tumours; separation and purification of biological molecules and cells; tissue engineering; MRI contrast heightening; and pharmacokinetic studies. Thus, it has opened up a vast field of research and application with its ability to deal with viral diseases in an efficient manner and address the problems posed by traditional antiviral medicines. It has also helped to overcome the problems related to drug solubility and bioavailability.
To know about the Research Methodology :- Request Free Sample Report
Global Antiviral Therapeutics Technologies Market Regional Insights:
North America is expected to dominate the global market by holding a revenue share of xx% during forecast period.
Growing prevalence of HIV and other viral infections in the region are expected to drive the market. For instance, as per the data published by CDC (Centre for Disease Control and Prevention), in 2020, the number of diagnoses of HIV infection in the U.S. were 38,281 (2017) and number of new hepatitis A, B, and C were 3,365, 3,409, and 4,225, respectively in 2017. Along with this, the growth of this region is mainly attributed due to increasing incestmetn in R&D and drug approval by FDA. In addition, to fuel the market growth in the current pandemic situation the federal government is providing support funds to pharmaceutical companies to help them to strengthen their clinical development pipelines.
The report also helps in understanding Global Antiviral Therapeutics Technologies Market dynamics, structure by analyzing the market segments and project the Global Antiviral Therapeutics Technologies Market size. Clear representation of competitive analysis of key players by product, price, financial position, product portfolio, growth strategies, and regional presence in the Global Antiviral Therapeutics Technologies Market make the report investor’s guide.
Scope of the report: Inquire before Buying
Global Antiviral Therapeutics Technologies Market By Region:
• North America
• Europe
• South America
• MEA
• APAC
Global Antiviral Therapeutics Technologies Market Key Players:
• Cipla
• Gilead Sciences
• F.Hoffmann-La Roche Ltd.
• GlaxoSmithKline plc.
• Bristol Myers Squibb
• Aurobindo Pharma
• Merck & Co.
• Johnson & Johnson
• AbbVie
• Schering-Plough Corporation.
• Abbott Laboratories
• Novartis International AG
• AstraZeneca
• Cocrystal pharma
• Daiichi Sankyo Co. Ltd.
• Janssen Pharmaceuticals, Inc.
Visit @:
This Report Is Submitted By : Maximize Market Research Company
About Us:
Maximize Market Research:
Maximize Market Research provides B2B and B2C research on 20,000 high growth emerging opportunities & technologies as well as threats to the companies across the Healthcare, Pharmaceuticals, Electronics & Communications, Internet of Things, Food and Beverages, Aerospace and Defense and other manufacturing sectors.
